Quantcast

Latest hepatitis C Stories

2014-09-17 08:29:54

Data shows recent plateau and drop in therapy utilization, but experts suggest new surge upon pending approval of new regimens WOONSOCKET, R.I., Sept. 17, 2014 /PRNewswire/ -- An analysis done by the CVS Health Research Institute provides insights regarding patients taking Sovaldi® (sofosbuvir), a new and expensive treatment for Hepatitis C introduced in December. The data shows that over the last several months (May through August 2014) there has been a plateau and actual...

2014-09-17 08:29:05

DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family...

2014-09-15 23:03:41

Complimentary Hayes, Inc. webinar reviews new management options and their effects on patient outcomes. Lansdale, PA (PRWEB) September 15, 2014 For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administration (FDA) a better way to manage the disease? Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—What You Need to Know is a...

2014-09-15 08:28:17

PITTSBURGH and HYDERABAD, India, Sept. 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Sofosbuvir is marketed by Gilead under the brand name Sovaldi®....

2014-09-11 08:28:27

NEW YORK, Sept. 11, 2014 /PRNewswire/ -- The AASLD/EASL Special Conference on Hepatitis C will discuss new therapeutic options that can cure the vast majority of patients with HCV, insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy. Members of the media interested in attending the conference may apply for a press pass by submitting their registration request and credential information to Ann Haran at aharan@aasld.org. Join us in New...

2014-08-30 23:04:47

Genomics R&D firm, Ryogen LLC, has been awarded two U.S. Patents – its 33rd and 34th – that are directed to polynucleotide sequences that play critical roles in Diabetes and Hepatitis C. Suffern, N.Y. (PRWEB) August 30, 2014 Ryogen LLC, an R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded two new patents, bringing the total number of its issued U.S. Patents to 34. U.S. Patent No. 8,795,959 titled “Isolated glucokinase genomic...

2014-08-19 12:29:09

Dr. Joseph Boscarino's research into disease that claimed his brother a major breakthrough DANVILLE, Pa., Aug. 19, 2014 /PRNewswire-USNewswire/ -- A Geisinger researcher on a personal crusade against hepatitis C has been nominated for a Centers for Disease Control and Prevention (CDC) award recognizing his unprecedented approach to addressing a major public health concern. http://photos.prnewswire.com/prnvar/20140819/137456 Joseph Boscarino, Ph.D. MPH, senior scientist, Geisinger...

2014-08-19 12:28:29

Reimbursement and Out-of-Pocket Costs are the Leading Reasons for Treatment Discontinuation, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 19, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of hepatitis C virus (HCV) infections, 40 percent of surveyed HCV treating specialists expect to prescribe Gilead's investigational fixed-dose combination of sofosbuvir/ledipasvir in the next six months to their genotype 1 patients. Analysis of...

2014-08-05 11:43:07

University of Pittsburgh Schools of the Health Sciences Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the results of a predictive model developed at the University of Pittsburgh Graduate School of Public Health. The results of the analysis, funded by the National Institutes of Health (NIH) and performed with the University of Texas MD Anderson Cancer Center, are...

2014-08-04 23:00:29

Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the results of a predictive model developed at the University of Pittsburgh Graduate School of Public Health Pittsburgh, Pennsylvania (PRWEB) August 04, 2014 Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the...


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related